First, we determined whether ATP6v1c1 was amplified or otherwise altered in patient tumors, using cBioportal, where we found that among 963 cases with gene sequencing data from the TCGA, 17.2% (163 of 963) of the tumors had an ATP6v1c1 gene amplification, while one tumor of the 963 had a gene deletion, and 2 had gene mutations; indicating that ATP6v1c1 gene amplification may be adaptive for breast tumors. The gene discussed is ATP6V1C1; the disease is neoplasm.